Steven G. Coca, DO, MS, is an Associate Professor of Medicine at the Icahn School of Medicine at Mount Sinai, the Associate Chair for Clinical and Translational Research for the Department of Internal Medicine, and the Director of Clinical Research for the Division of Nephrology.
Dr. Coca’s research accomplishments are diverse and far-reaching: he has focused research efforts on short- and long-term outcomes of acute kidney injury, and assessing performance of biomarkers for rapid diagnosis and risk stratification in AKI. His research has advanced understanding of the clinical utility of prognostic, predictive, and efficacy biomarkers for CKD/diabetic kidney disease in several large cohort studies, including ACCORD, VA NEPHRON-D, CANVAS, and the Mount Sinai BioMe Biobank. Most recently, he has collaborated to advance use of machine-learning techniques and multidimensional data acquisition to create risk-stratification tools for patients at risk or with prevalent chronic kidney disease, and studied the impact of exercise on longitudinal changes in the kidney.
Since 2005, Dr. Coca has published numerous peer-reviewed research articles, reviews, and editorials, and has given numerous invited talks at national and international conferences and academic medical centers. He has engaged in multiple collaborative efforts in translational and clinical research, and served as a research mentor for many fellows, residents, medical students, and junior faculty members. He also serves on the editorial boards for the Journal of the American Society of Nephrology, the Clinical Journal of the American Society of Nephology, and Kidney International, and as an Associate Editor for Kidney360, and is a frequent reviewer on NIH study sections.
Dr. Coca received his D.O. degree from the University of New England College of Osteopathic Medicine, and completed his residency and nephrology fellowship at the Yale University School of Medicine. He received his Master of Science in Epidemiology and Public Health from the Yale University Graduate School of Arts and Sciences.
Certifications
Nephrology
Clinical Focus
- Acute Renal Failure
- Acute Tubular Necrosis
- Chronic Renal Failure
- Dialysis
- Glomerulonephritis
- High Blood Pressure
- Hypertension (High Blood Pressure)
- Nephrotic Syndrome
Education
DO, University of New England
MS, Yale University Graduate School of Arts and Sciences
Residency, Internal Medicine, Yale University School of Medicine
Fellowship, Nephrology, Yale University School of Medicine
-
2013
AFMR 2013 Junior Physician Investigator Award -
2008
T. Franklin Williams Scholar -
2008
K23 Career Development Award -
2008
NIH Loan Repayment Program -
2007
Henry Christian Award -
2005
Intern of the Year -
Midcareer Distinguished Researcher Award, -
Top 5 Reviewer of the Year -
Top 5 Reviewer of the Year -
MSIP “Deal of the Year Award” -
Top 5 Reviewer of the Year, -
Top 5 Reviewer of the Year, -
4D Technology Development Program Award -
Henry Christian Award
Dr. Coca is actively involved in clinical and translational research that focuses on using biomarkers to improve risk-stratification for outcomes in acute and chronic kidney disease. The development of prognostic and predictive biomarkers may aide future clinical trials, by serving as an enrichment strategy for enrollment, and may also serve as outcomes for early phase trials of novel interventions. He has leveraged existing cohorts with banked blood and urine samples, including the TRIBE-AKI consortium, and the ACCORD trial participants to explore the prognostic, discriminative, and additional value of biomarkers in AKI and CKD. He plans to continue exploring these parameters in other large cohorts and then to design innovative trials employing biomarkers for facilitated enrollment and for better determination of efficacy of existing or new agents.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Coca during 2020 and/or 2021. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Company Founder:
- RenalytixAI
Consulting:
- Axon Therapies; Bayer; CHF Solutions, Inc; Relypsa; RenalytixAI; Reprieve Cardiovascular; Tucker Ellis, LLC
Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)
- Verici
Other Activities: Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership.
- inRegen
Royalty Payments:
- RenalytixAI
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.